Monday, April 29, 2024 11:05:54 PM
Recent SNTI News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/17/2024 09:19:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 09:17:02 PM
- Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia • GlobeNewswire Inc. • 05/13/2024 12:15:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:15:14 PM
- Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights • GlobeNewswire Inc. • 05/09/2024 08:05:33 PM
- Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) • GlobeNewswire Inc. • 04/30/2024 12:05:36 PM
- Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights • GlobeNewswire Inc. • 03/21/2024 08:05:49 PM
- Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program • GlobeNewswire Inc. • 01/05/2024 09:05:00 PM
- Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia • GlobeNewswire Inc. • 12/22/2023 11:30:00 AM
- Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates • GlobeNewswire Inc. • 11/13/2023 09:15:00 PM
- Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China • GlobeNewswire Inc. • 11/06/2023 09:05:00 PM
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting • GlobeNewswire Inc. • 10/31/2023 01:06:00 PM
- Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting • GlobeNewswire Inc. • 09/27/2023 01:05:00 PM
- Senti Bio to Participate in Upcoming Conferences • GlobeNewswire Inc. • 09/26/2023 08:05:00 PM
- Senti Bio to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/05/2023 12:30:00 PM
- Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates • GlobeNewswire Inc. • 08/11/2023 12:35:00 PM
- Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners • GlobeNewswire Inc. • 08/10/2023 12:35:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM